Percutaneous transluminal coronary angioplasty or PCTA balloons are instantly inflated, after arriving at the desired position, inside a blocked coronary artery for clearing up the blockage, widen the artery and permit smooth blood flow. The balloon is passed into the narrow arteries with the help of a wire which is generally a catheter. The global PTCA balloon catheter market is anticipated to grow at a CAGR of 4.25% between 2019 and 2027, as per the market analysis carried out by Inkwood Research.
The growing geriatric population and rise in the incidences of cardiovascular diseases are anticipated to drive the growth of PTCA balloon catheters market. The product and delivery platform of the PTCA balloon catheter market is used extensively for various purposes. Availability of alternative therapies and the high cost of balloons and stents are the major factors hindering the PTCA balloon catheter market.
The global PTCA balloon catheters market has been geographically segmented into North America, Europe, Asia Pacific and the Rest of World.
The Asia-Pacific region is predicted to comprise the fastest-growing regional market for the PTCA balloon catheters. The region’s dense population and the various developing countries that are undergoing urbanization and economic development are significant for the market growth. The urbanization has subsequently increased the disposable income of people, giving rise to lifestyle changes such as alcohol consumption and smoking, unhealthy food habits, and physical inactivity. These changes can trigger obesity and diabetes among the population with a higher rate of CVDs that will be driving the PTCA balloon catheters market in APAC.
B Braun Melsungen AG, Cardinal Health Inc., Terumo Corporation, Boston Scientific Corporation, Microport Scientific Corporation, Medtronic PLC, Cordis, Abbott Laboratories, C. R. Bard, Inc., Cook Medical LLC, Spectranetics, Endocor GmbH, and Biotronik Se & Co. KG are the major companies operating in the global market.